Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer
Chu-Cheng Chang,Pei-Ching Lin,Chun-Chi Lin,Yuan-Tzu Lan,Hung-Hsin Lin,Chien-Hsing Lin,Shung-Haur Yang,Wen-Yi Liang,Wei-Shone Chen,Jeng-Kai Jiang,Jen-Kou Lin,Shih-Ching Chang
DOI: https://doi.org/10.3390/ijms18071441
IF: 5.6
2017-07-05
International Journal of Molecular Sciences
Abstract:We compared the clinicopathological and molecular profiles between different age groups of sporadic colorectal cancer (CRC) patients (age <50, 56-60, 60-70, 70-80, and >80); 1475 CRC patients were enrolled after excluding 30 individuals with Lynch syndrome. The mutation spectra for <i>APC</i>, <i>TP53</i>, <i>KRAS</i>, <i>PIK3CA</i>, <i>FBXW7</i>, <i>BRAF</i>, <i>NRAS</i>, <i>HRAS</i>, <i>TGFbR</i>, <i>Akt1</i>, and <i>PTEN</i> were analyzed using polymerase chain reaction (PCR), followed by MassArray and microsatellite (MSI-high) analysis by performing genotyping. Male patients (74.1%) were significantly predominant to females (25.9%) in the older age group (70-80, >80). There was an insignificantly linear trend between TNM staging and age-onset of CRC diagnosis. Patients aged < 50 had 58.7% diseases in the advanced stages (Stage III: 36.5% and IV: 22.2% respectively), while this decreased to 40.2% (Stage III: 26.2% and IV; 14.0% respectively) in patients >80. The distributions of mutation frequency were similar in majority of the genes studied among different age groups. Additionally, patients aged <50 had significantly higher frequency of MSI-high, <i>PTEN</i>, and <i>HRAS</i> mutations than those of other groups. Age-onset at diagnosis significantly affected overall survival (HR = 1.46; 95% CI: 1.35-1.58), but not cancer-specific survival (HR = 1.08; 95% CI: 0.99-1.18) in multivariate analysis. In conclusion, molecular and clinicopathological differences were not as significant among different age groups of CRC patients as previously suspected.
biochemistry & molecular biology,chemistry, multidisciplinary